AAMD Presentation
-
Upload
lee-culp-ms-cmd-rtt -
Category
Documents
-
view
23 -
download
3
Transcript of AAMD Presentation
![Page 1: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/1.jpg)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Supine verses Prone Intact Breast Treatment: The OSU ApproachKarla Kuhn, CMD, RT(R)(T)Lee Culp, MS. CMD, RT(T)
June 2016
![Page 2: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/2.jpg)
2
I have no disclosures relative to the presented material
The following presentation is a reflection of studies, protocols, and opinions
No Honorarium has been received in regards to the subsequent material
Disclosures
![Page 3: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/3.jpg)
3
Karla Kuhn, CMD RT(R)(T) 9 years Radiation Therapist 10 years in July as a
Dosimetrist Lead Dosimetrist at
SSCBC in August 2014
Meet the Speaker
![Page 4: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/4.jpg)
4
The James Cancer Hospital – “The Main” All sites except Breast 7 Vaults 1 PET/CT 1 CT 1 MRI 1 HDR Unit 1 Gamma Knife Unit 13 Radiation Oncologists 12 Radiation Physicists 11 Medical Dosimetrists 36 Radiation Therapists
Radiotherapy at OSU
![Page 5: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/5.jpg)
5
SSCBC All Breast and Breast mets 2 Vaults 1 CT 5 Radiation Oncologists 1-2 Radiation Physicists 2 Medical Dosimetrists 8 Radiation Therapists 3 Nurses
Radiotherapy at OSU
![Page 6: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/6.jpg)
6
The Stefanie Spielman Comprehensive Breast Center (SSCBC)
at the Ohio State University
Our Clinic
Opened in January 2011
![Page 7: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/7.jpg)
7
Comprehensive Patient-Centered Care
Staff at SSCBC Always receiveshigh patient satisfaction scores quarterly & yearly
300-450 patients come to SSCBC each day
![Page 8: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/8.jpg)
8
Analytic Breast Cancer patient by Fiscal Year [July 1-June 30]
![Page 9: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/9.jpg)
9
Supine 2D Done by Simulator Borders marked visually by MD with wire Used borders to indicate field size using half-beam
blocked technique Gantry angle chosen from crossing of medial and lateral
wires Standard of 2 cm of lung treated Used mobile contour plotter to achieve a 2D treatment
plan
Evolution of Breast Planning
![Page 10: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/10.jpg)
10
3D Free Breathing DIBH Prone Done by CT Simulator Border is marked visually by MD with wires to use as a
guide when contouring Dosimetrist contours Organs at Risk; MD contours target
volumes Dosimetrist utilizes all 3D tools: Conformal, and if
necessary, IMRT planning to achieve our Dosimetric goals
Evolution of Breast Planning (cont’d)
![Page 11: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/11.jpg)
11
Post-Op External Beam Partial Breast Irradiation IORT & HDR Partial Breast Irradiation
Future of Breast Planning: Protocol OSU 13282 – Feasibility of assessing Radiation Response with MRI/CT Directed Pre-Op Accelerated Partial Breast Irradiation in the Prone Position for Hormone Response early stage Breast Cancer
Evolution of Breast Planning (cont’d)
![Page 12: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/12.jpg)
12
Images of Breast Anatomy
1http://fitsweb.uchc.edu/student/selectives/Luzietti/Breast_anatomy.htm
![Page 13: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/13.jpg)
13
Breast Anatomy
Clinical Borders of Breast Medial: Sternum Lateral: Midaxillary line Cranial: 2nd Rib Caudal: 6th RibMost Breast Cancers are located in the upper outer quadrant of the breast Greatest Percentage of breast tissueLeft sided breast cancers are more common
![Page 14: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/14.jpg)
14
Lymphatics of Breast AnatomySupraClav Borders: Cranial to Cricoid Cartilage Caudal to edge of Clavicular Head Lateral Junction 1st rib & clavicle Medial Excludes Thyroid & Trachea
Axilla Borders (I-III): Cranial Pec Minor insert on coracoid process Caudal Pec Major insert on Ribs Lateral Latissumus Dorsi Medial Chestwall
Internal Mammary: Cranial Top 1st intercostal space Caudal Bottom 3rd intercostal space
![Page 15: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/15.jpg)
15
Levels of Axillary Nodes (I-III) – Primary DrainageLevels of Axillary Lymph Nodes:
Level I: Lateral to the pectoralis minor muscle. Usually involved first.
Level II: Posterior to the pectoralis minor muscle.
Level III: Medial to the pectoralis minor muscle. - Unlikely to be involved if levels I & II are negative
2http://www.surgicalcore.org/popup/50927
![Page 16: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/16.jpg)
16
Epidemiology, Pathology, and Risk Factors of Breast Cancer
![Page 17: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/17.jpg)
17
Most commonly diagnosed cancer among women
182,000 women diagnosed annually in the US
Yearly ~40,000 women die of Breast Cancer
Second leading cause of cancer death among women after lung cancer
Lifetime risk of dying from Breast Cancer 3.4%
Epidemiology
![Page 18: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/18.jpg)
18
Fine Needle Aspiration Very small needle to extract fluid or cells from the abnormal area Surgical Biopsy Whole abnormal area, plus some surrounding normal tissue, is removed Core Needle Biopsy *Recommended* Large hollow needle to remove one sample of breast tissue per insertion
Pathology
![Page 19: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/19.jpg)
19
Estrogen (ER) & Progesterone (PR) assays routinely performed on biopsied tissue
Correlate with prognosis & tumor response to chemo & hormonal agents Her-2+ – proto-oncogene assay used to
assess overexpression in invasive breast carcinomas. Outcomes have improved with targeted therapy (Herceptin)
Her-2+ is associated with poorer prognosis, historically. Outcomes have improved with targeted therapy Her-2- is encouraging when hormone assay is positive
Pathology
![Page 20: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/20.jpg)
20
Female (100x’s more likely than men) Age 55+ Inherited Genes (BRCA1 & BRCA2) Strong Family History of Breast Cancer Race & Ethnicity (White women) Dense Breast Tissue Menstruation prior to age 12 Menopause after age 55 Prior radiation to chest
Inherent Risk Factors
![Page 21: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/21.jpg)
21
Consuming alcohol Overweight/Obese Reduced Physical Activity First child born after age 30 Birth Control (oral & Depo-shot) Hormone therapy after menopause
Lifestyle Risk Factors
![Page 22: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/22.jpg)
22
Stage 0 – DCIS (in situ)
Stage I – Invasive (IA & IB)
- Tumor up to 2cm
- Cancer not spread outside breast (no lymph involvement)
Stage II – Invasive (IIA & IIB)
- Tumor 2-5cm
- Spread to local Lymph Nodes
Staging – AJCC
![Page 23: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/23.jpg)
23
Stage III – Invasive (IIIA, IIIB, & IIIC)
- Numerous positive lymph nodes
- Tumor is larger than 5cm
- Location of positive lymph nodes & skin involvement may
change stage from IIIA to IIIC
Stage IV – Spread beyond breast & lymph nodes to other
organs of the body (Lung, bone, liver, brain)
Staging – AJCC (Cont’d)
![Page 24: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/24.jpg)
24
T – Size of the primary Tumor
- TX, T0, Tis, T1, T2, T3, T4
N – Lymph Node Involvement
- NX, N0, N1, N2, N3
M – Metastasis
- MX, M0, M1
Staging – TNM
![Page 25: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/25.jpg)
25
Lower Stage – Surgery & Radiation
Higher Stage – Chemotherapy & Radiation
BRCA+ - Mastectomy
Staging – Treatment Modalities
![Page 26: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/26.jpg)
26
Rationale Supine vs. Prone in
Breast Radiotherapy
![Page 27: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/27.jpg)
27
Radiotherapy for WBI in the supine position is standard
Large, pendulous breasts can be problematic
-Displacement of breast laterally, inferiorly -Accentuates skin folds Excessive lung & heart
included in some cases Contour extends beyond
CT field-of-view
Challenges of Breast Radiotherapy for Patients with Large BMI
![Page 28: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/28.jpg)
28
Large Patient BMI: Technical Challenge for Radiotherapy
Irradiation of skin folds: - Moist Desquamation - Telangiectasia
![Page 29: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/29.jpg)
29
Facility Challenges
CT Bore Diameter - Standard ~80 cm. - Wide ~65 cm.Cuts off patient contourError in dose model
![Page 30: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/30.jpg)
30
Patients with larger and/or pendulous breasts to reduce the toxicity and improve breast appearance long term
Left sided breast cancer patients to avoid the heart & lung Small Breast benefits due to decrease in lung dose Cases where maximal lung avoidance is desirable such as
smokers, severe COPD
Approximately 60% of patients at SSCBC undergoing post-lumpectomy breast radiotherapy are treated in prone position
Indications for Prone Breast Radiotherapy
Expertise in prone WBRT varies widely between institutions, resulting in mixed findings regarding the degree of heart sparing with this technique6,7
3 Kirby et al. Radiother Oncol 96: 178-84, 2010. 4 Bartlett et al. Radiother Oncol 114: 66-72, 2015
![Page 31: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/31.jpg)
31
Better dose homogeneity due to smaller separation
Reduces skinfolds Distances the breast from
the chestwall Reduction in chestwall
Motion
Indications for Prone Breast Radiotherapy (Cont’d)
However, WBRT has also been associated with excess non-breast cancer mortality, predominantly related to ischemic cardiac disease*
5 EBCTCG. Lancet 378(9804): 1707-16, 2011.
![Page 32: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/32.jpg)
32
n = 46 WBI – Field-in-field (5-6) - WB dose: 50.4 Gy/1.8 Gy/28 fx - boost: supine Left Anterior Descending
Artery (LAD) dose: - V20 & V40 significantly higher in the prone position versus supine
Incidental Dose to Coronary Arteries is Higher in Prone Than in Supine Whole Breast Irradiation
6 Wurschmidt et al, Strahlenther Onkol 2014
![Page 33: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/33.jpg)
33
Patient population: women diagnosed with stage I-II invasive carcinoma or DCIS of the left breast who received WBRT in the prone position post-lumpectomy
a) Cohort 1: first 20 patients treated consecutively beginning in January 2014
b) Cohort 2: last consecutive 20 patients treated prior to August 2015
Breast and lumpectomy target volumes, heart, and lungs contoured following CT simulation
LAD contoured retrospectively on each case
Retrospective SSCBC study on the Learning Curve in Cardiac Sparing with Prone left Whole
Breast Radiothearpy
Results
![Page 34: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/34.jpg)
34
Cohort 1 Cohort 2
Stage IA (pT1cN0) ER+/PR+/Her2- G1 IDCBMI = 31Breast PTV (cm3) = 710Dose: 50 Gy + 10 Gy boost
![Page 35: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/35.jpg)
35
Heart Left Lung Right Lung Contralateral Breast Sternum Thyroid
RTOG 1005 & 1304; Organs at Risk
![Page 36: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/36.jpg)
36
Breast CTV – Includes palpable breast tissue demarcated with radio-opaque markers at CT simulation, the apparent CT glandular breast tissue visualized by CT, consesus definitions of anatomical borders, and the Lumpectomy CTV from the breast cancer atlas.
Breast PTV – Breast CTV + 7mm 3D expansion (exclude heart and does not cross midline)
Breast PTV Eval – Edited copy of Breast PTV limited anteriorly to exclude the part outside the patient and the first 5 mm of tissue under the skin and posteriorly is limited no deeper to the anterior surface of the ribs
RTOG 1005 & 1304; Expansions & Evals
*In Prone (and Supine DIBH) at SSCBC the CTV to PTV expansion is reduced to 5mm due to limited chestwall motion
![Page 37: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/37.jpg)
37
Lumpectomy GTV – Includes excision cavity volume, architectural distortion, lumpectomy scar, seroma and/or extent of surgical clips
Lumpectomy CTV – Lump GTV + 1cm 3D expansion Lumpectomy PTV – Lump CTV + 7mm 3D expansion
(excludes heart) Lump PTV Eval – Copy of Lump PTV which is edited.
Limited to exclude the part outside the ipsilateral breast and the first 5mm of tissue under the skin.
RTOG 1005 & 1304; Expansions & Evals
![Page 38: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/38.jpg)
38
Targets Contoured:
![Page 39: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/39.jpg)
39
DRR Field Placement
Goal: 95% Dose to 95% Volume
![Page 40: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/40.jpg)
40
Constraints & Goals
RTOG 1005 & 1304 SSCBCIdeal Acceptable
Breast PTV Eval 95%/95% 90%/90%Lump PTV Eval 100%/100% 100%/95%50% Breast PTV Eval <108% <112%VBreast Receiving Boost Dose 30% 35%Heart Mean <200cGy <200cGyLung V20 10% 15%Contra Breast Max <300cGy <330cGy
Ideal AcceptableBreast PTV Eval 95%/95% 90%/90%Lump PTV Eval 95%/95% 90%/90%50% Breast PTV Eval <108% <112%VBreast Receiving Boost Dose 30% 35%Heart Mean <400cGy <500cGyLung V20 15% 20%Contra Breast Max <300cGy <330cGy
*Boost (when indicated) & Whole Breast planned simultaneously in Prone Position. Constraints & Goals evaluated in Plan Sum.
![Page 41: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/41.jpg)
41
Boost is planned at time of Initial plan Boost is in Prone position as well Plan evaluated in Plan Sum Ski slope V54 108% dose < 50% volume “Simultaneous Boost” hotspot placed in the Lump PTV Eval
Prone with Boost
“Ski Slope”108%
![Page 42: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/42.jpg)
42
Guidelines for SSCBC Boost: Any Stage No Lymph Nodal Involvement Hormone Receptor positive <50+ years old No prior chemotherapy
To Boost, or Not to Boost?
![Page 43: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/43.jpg)
43
SSCBC Guidelines for Hypofractionation Stage 1 or 2 No Lymph Nodal Involvement Hormone Receptor positive 60+ years (sometimes women 50+ years) No prior chemotherapy
Hypofractionated/Canadian Fractionation
Hypofractionated Prescription: 2.66Gy * 16 FX = 42.56Gy
Standard Fractionation2.0Gy * 25 FX = 50.0 Gy
VS.
![Page 44: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/44.jpg)
44
Supine vs. Prone
• Small Breasts• Left Sided
![Page 45: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/45.jpg)
45
Supine vs. Prone DVH (Small Breast, LT side)
![Page 46: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/46.jpg)
46
Free Breathing
Deep Inspiration Breath Hold
(DIBH)
VS..
![Page 47: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/47.jpg)
47
Free Breathing vs. Supine DIBH
- DIBH- Free Breathing
![Page 48: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/48.jpg)
48
DIBH
Prone
VS.
![Page 49: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/49.jpg)
49
Supine DIBH vs. Prone
- Prone- DIBH
![Page 50: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/50.jpg)
50
Vendor Manufactured Breast Board
Extra mobilization devices are used for
patient comfort
![Page 51: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/51.jpg)
51
Face Down Option
![Page 52: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/52.jpg)
52
Index Immobilization MD wires Lumpectomy scar & Breast Borders Patient starts low on hands & knees before laying down. Inframammary fold
should fall just above the inferior opening of the insert Smoothing of the belly tissue may be needed Elbows bent in Vac-bag to ensure arm reproducibility & comfort. Location of
headrest is marked Contra breast should be gently pulled “down & out” and rest on the sternal sponge Head turned toward the contra side Back should be as flat as possible with shoulders relaxed
CT Prone Positioning
![Page 53: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/53.jpg)
53
5 Tattoos
Ipsilateral Tattoo
Board number on index bar in line with mid-nipple or other designated breast mark
![Page 54: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/54.jpg)
54
5 Tattoos (cont’d)
3 PA Tattoos
Contralateral Tattoo
![Page 55: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/55.jpg)
55
Always performed with physician present Orthogonal films taken for isocenter
verification Double exposure of each treatment field is
acquired PA, lateral, and treatment SSDs are
verified Physician clinically visualizes treatment
fields on the patient
Verification Simulation
![Page 56: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/56.jpg)
56
Patient adjusted Right to Left, Sup and Inf, and rolled to align tattoos to lasers.
Treatment Setup
Board number on index bar in line with mid-nipple or other designated breast mark
*important to leave Lateral table position at 0
![Page 57: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/57.jpg)
57
Daily Shifts are made to isocenter PA and Lateral SSD is checked
Treatment Setup (cont’d)
Lateral SSD is checked DAILY to verify how tight the contralateral breast is pulled and verifies correct lateral position
![Page 58: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/58.jpg)
58
Belly Board Technique
Egg crate opening reduces pressure to the abdomen
![Page 59: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/59.jpg)
59
Custom Styrofoam Insert
- May be used to keep contralateral breast out of treatment field
- Contralateral breast is marked on Styrofoam insert
![Page 60: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/60.jpg)
60
Improves set-up of contralateral breast
![Page 61: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/61.jpg)
61
Integrated Team of Specialists Full Patient Compliance and Understanding
Proper Equipment Established Policy & Procedure
Key Components for Successful Prone Treatments
![Page 62: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/62.jpg)
62
Dr. Julia White Dr. Jose Bazan Dr. Jessica Wobb Dr. Ashley Sekhon Steven Kalister (Administrator SSCBC) Tina LaPaglia (Lead Therapist SSCBC)
References/Contributions
![Page 63: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/63.jpg)
63
Thank YouTo learn more about Ohio State’s cancer program, please visit cancer.osu.edu or
follow us in social media:
![Page 64: AAMD Presentation](https://reader036.fdocuments.net/reader036/viewer/2022081513/587e19021a28abbc2e8b5b9d/html5/thumbnails/64.jpg)
64